US OptionsDetailed Quotes
DAVE240920C30000
- 10.42
- +1.72+19.77%
15min DelayClose Aug 23 16:00 ET
10.52High10.40Low
10.40Open8.70Pre Close2.00K Volume3.64K Open Interest30.00Strike Price2.10MTurnover83.63%IV2.48%PremiumSep 20, 2024Expiry Date9.44Intrinsic Value100Multiplier26DDays to Expiry0.98Extrinsic Value100Contract SizeAmericanOptions Type0.9111Delta0.0182Gamma3.96Leverage Ratio-0.0306Theta0.0187Rho3.61Eff Leverage0.0170Vega
Dave Inc Stock Discussion
Sign in to post a comment
While the others take big losses selling everything they have, I feel the more rational decision is to do nothing.
The tech sector, specifically semiconductors and Ai/crypto companies, aren't going anywhere. NVDA isn't going to just shrug their shoulders and give up tomorrow.
So long as you have researched and relied on financials, I think it will all come back and probably stronger than ever.
In the meantime, I've added to a couple of "defense" stocks:
$ADMA Biologics (ADMA.US)$ : 58.8% U...
The tech sector, specifically semiconductors and Ai/crypto companies, aren't going anywhere. NVDA isn't going to just shrug their shoulders and give up tomorrow.
So long as you have researched and relied on financials, I think it will all come back and probably stronger than ever.
In the meantime, I've added to a couple of "defense" stocks:
$ADMA Biologics (ADMA.US)$ : 58.8% U...
4
3
Today grabbing
$Dave Inc (DAVE.US)$
PT $41+ SL $27
$Desktop Metal (DM.US)$
LT PT: $17+
$Hims & Hers Health (HIMS.US)$
LT PT: $39.27+
$Intel (INTC.US)$
PT: $50 SL: $25
Medium duration, 14-30 days min.
$Dave Inc (DAVE.US)$
PT $41+ SL $27
$Desktop Metal (DM.US)$
LT PT: $17+
$Hims & Hers Health (HIMS.US)$
LT PT: $39.27+
$Intel (INTC.US)$
PT: $50 SL: $25
Medium duration, 14-30 days min.
3
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings (SWVL.US)$718.40%
![]()
$Root Inc (ROOT.US)$564.60%
![]()
$Elevation Oncology (ELEV.US)$561.08%
![]()
$JanOne (JAN.US)$554.05%
![]()
$GeneDx Holdings (WGS.US)$520.71%
![]()
$Corbus Pharmaceuticals (CRBP.US)$513.25%
![]()
$AGBA Group (AGBA.US)$482.90%
![]()
$Janux Therapeutics (JANX.US)$431.22%
![]()
$Dave Inc (DAVE.US)$4...
A quick recap for the month ending April 30, 2024.
4
1
Despite strong revenue growth, Dave's low P/S ratio may indicate investor belief of underperformance in the broader industry. Shareholders may think recent performance has peaked, leading to lower selling prices. The low P/S ratio could signal price risks if medium-term revenue trends persist, but investors anticipate future revenue volatility.
Dave Inc.'s CEO, Jason Wilk, sees the recent transaction as a major advancement for the company, offering a unique chance to increase shareholder value. He remains confident in the company's ability to meet its growth and profitability goals in the future quarters.
$Dave Inc (DAVE.US)$ Something not right… it is now at 9.05
Despite strong revenue growth that outpaces the industry, Dave's P/S ratio is surprisingly low. This could suggest underlying risks to the company's future performance as investors may not be convinced the company can maintain its recent growth rates.
$Dave Inc (DAVE.US)$ what a bunch of clowns. Stellar revenue. and it will get better and better
$Dave Inc (DAVE.US)$ reverse stock split coming. 1 for 2
No comment yet
Shootingstar : Yes the world at this stage cannot do without tech. This will be a highly innovative tech driven era to produce the highest efficiency with the minimal diminishing resources used.
Chong Kong Hui : AI simply overrated and AI stocks over priced, time will tell.
Paul Anthony : for young people